🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "huge turning point" in the effort against superbug strains of the pathogen, according to health experts.

An International Health Concern

Gonorrhoea infections are increasing around the world, with figures suggesting over 82 million infections annually. Particularly high rates are reported in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the context of rising global incidence, increasing antimicrobial resistance and the very limited treatment choices currently available.”

Health officials are increasingly worried about the increase in drug-resistant strains. The global health body has classified it as a "priority pathogen". Recent surveillance showed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Drugs Receive Authorization

Zoliflodacin, also known as a brand name, was authorized by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GSK, gained clearance in the same week. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to develop it.

“This milestone marks a significant shift in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Results and Global Access

As per data detailed in a major medical journal, zoliflodacin cured the vast majority of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which combines two antibiotics. The research involved nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the authority to make available and distribute the drug in many low-income and middle-income countries.

Clinicians on the front lines have expressed positive views. Access to a single-dose, oral treatment of this kind is described as a "game-changer" for gonorrhoea control. This is viewed as essential to alleviate the strain of the infection for individuals and to halt the transmission of untreatable gonorrhoea around the world.